Rheuma tv 
According to a recent study published in Clinical Rheumatology, patients with COVID-19 have a 43% higher chance of developing new autoimmune disorders in the 3 to 15 months after an acute infection. Dr. Tesch and colleagues used routine patient healthcare information from Germany to conduct a matched cohort research to investigate the risk for new-onset … Read more
Recently, a novel dietary strategy known as the Very Low-Calorie Ketogenic Diet (VLCKD) has been proposed as a viable treatment option for certain disorders that have similarities with fibromyalgia (FM) in terms of their clinical and pathophysiological characteristics. According to a recent study published in Frontiers in Nutrition, a 20-week VLCKD program in FM patients … Read more
According to studies published in The Lancet Rheumatology, people with hip or knee osteoarthritis (OA) who exercise fare better than patients who do not, thereby corroborating the positive effect of therapeutic exercise on pain and physical function. Dr. Holden and colleagues performed a systematic review and meta-analysis to evaluate individual patient-level moderators on the effects … Read more
A small protein called CD24, which is glycosyl-phosphoinositol-anchored and sends T cells costimulatory signals, has been linked to the onset of autoimmune illness. According to a recent study published in the Annals of Medicine, soluble CD24 (sCD24) may serve as a biomarker of inflammation in patients with rheumatoid arthritis (RA), particularly in early and seronegative … Read more
A novel non-antibody biological CD40L antagonist named dazodalibep is currently under investigation as a potential therapy for autoimmune diseases. The results of the phase 2 MIDORA trial, published in the journal Rheumatic & Musculoskeletal Diseases (RMD) Open, reported the efficacy and safety of dazodalibep in patients with moderate-to-severe active rheumatoid arthritis (RA). Dr. Kivitz and … Read more
According to research published in Rheumatology, nintedanib reduces the decline of lung functionality in patients with limited cutaneous systemic sclerosis (SSc) and interstitial lung disease (ILD). Dr. Allanore and colleagues conducted the SENCIS and SENCIS-ON trials to investigate the progression of ILD and the effects of nintedanib in patients with limited cutaneous SSc. In the … Read more
According to a recent study published in Frontiers in Immunology, the combination of tofacitinib and iguratimod is superior to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with a greater response rate in rheumatoid arthritis (RA)-usual interstitial pneumonia (UIP). The combination therapy has the potential to simultaneously reduce both RA and RA-UIP. In a prospective observational cohort … Read more
According to data published in Arthritis Care & Research, the introduction of tumor necrosis factor inhibitors (TNFi) in 2003 was not successful in preventing fracture rates in individuals with ankylosing spondylitis from more than doubling from 2000 to 2020. Dr. Sali Merjanah and his team evaluated the trends in fracture risk among individuals with ankylosing … Read more
A multidisciplinary strategy, comprising physical exercise therapy, occupational therapy, patient self-management, and pharmaceutical therapy, is necessary for the ideal care of rheumatoid arthritis (RA). According to a recent study published in Healthcare (Basel), the combination of occupational therapy and physical exercise improves the quality of life for rheumatoid arthritis (RA) patients. Cerasola and colleagues conducted … Read more